Hisatsugu Goto

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity

Seidai Sato, Shintaro Shinohara, Shinya Hayashi et al. · Respiratory Research · 2017 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Role of Platelet-Derived Growth Factor/Platelet-Derived Growth Factor Receptor Axis in the Trafficking of Circulating Fibrocytes in Pulmonary Fibrosis

Yoshinori Aono, Masami Kishi, Yuki Yokota et al. · American Journal of Respiratory Cell and Molecular Biology · 2014 · 93 citations

Medicine, Cell Biology, Pharmacology +14

A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody

Shinji Abe, Yuki Morita, Mika K. Kaneko et al. · The Journal of Immunology · 2013 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17